

any theophylline-erythromycin interaction remains questionable, particularly in view of the already wide interpatient variability intrinsically associated with theophylline pharmacokinetics.^{6,7} If such an interaction really exists, it appears to be minimal when compared to other recently characterized drug-drug interactions (eg, digoxin-quinidine).⁸ Until an effect of erythromycin on theophylline pharmacokinetics is more rigorously established, empiric recommendations for dosage adjustment in patients receiving concomitant erythromycin may be premature.

Michael S. Maddux, Pharm.D., Assistant Professor of Pharmacy Practice; and Jerry L. Bauman, Pharm.D., Assistant Professor of Pharmacy Practice, College of Pharmacy, University of Illinois at Chicago, Chicago

REFERENCES

- 1 Danan G, Descatoire V, Pessayre D. Self-induction by erythromycin of its own transformation into a metabolite forming an inactive complex with reduced cytochrome P-450. *J Pharmacol Exp Ther* 1981; 218:509-14
- 2 Prince RA, Wing DW, Weinberger MM, Hendeles LS, Riegelman S. Effect of erythromycin on theophylline kinetics. *J Allergy Clin Immunol* 1981; 68:427-32
- 3 May DC, Jarboe CH, Ellenburg DT, Roe EJ, Karibo J. The effects of erythromycin on theophylline elimination in normal males. *J Clin Pharmacol* 1982; 22:125-30
- 4 LaForce CF, Miller MF, Chai H. Effect of erythromycin on theophylline clearance in asthmatic children. *J Pediatr* 1981; 99:153-56
- 5 Richer C, Mathieu M, Rah H, et al. Theophylline kinetics and ventilatory flow in bronchial asthma and chronic airflow obstruction: Influence of erythromycin. *Clin Pharmacol Ther* 1982; 31:579-86
- 6 Jenne JW, Wyze MS, Rood FS, McDonald FM. Pharmacokinetics of theophylline application to adjustment of the clinical dose of aminophylline. *Clin Pharmacol Ther* 1972; 13:349-60
- 7 Powell JR, Vozeh S, Hopewell P, et al. Theophylline disposition in acutely ill hospitalized patients. *Am Rev Respir Dis* 1978; 118:229-38
- 8 Mungall DR, Borichaux RP, Perry W, et al. Effects of quinidine on serum digoxin concentration. *Ann Intern Med* 1980; 93:689-93

Beryllium Disease Necessity for Continuing Surveillance

To the Editor:

Three cases of chronic beryllium disease diagnosed between 1978 and 1980 were recently reported to the Beryllium Case Registry (BCR) of the National Institute for Occupational Safety and Health (NIOSH). All three were machinists who fabricated beryllium metal parts for missile guidance systems in a large aerospace manufacturing plant in California. A review of environmental survey data suggests that levels of exposure to beryllium dust exceeded prevailing occupational exposure standards during the 1960s and early 70s, and were likely responsible for the subsequent development of the disease.

Acute beryllium disease was first reported in the European literature in 1933.¹ In the United States, hundreds of cases of acute and chronic beryllium disease were documented during the 1940s and 50s.² After recognition of the serious health hazard associated with beryllium, control of exposure led to a reduced number of both acute and chronic cases.³ During the period of 1973 through 1977, 55 cases were added to the Registry, for an average of 11 per year.⁴ During the five years which followed (through 1982), only ten cases

were added, making the current number 897.

Beryllium phosphor was once used in fluorescent lighting tubes. Although this major use was discontinued in 1949, beryllium's many industrial uses and the resultant opportunities for toxic exposure still exist. Major consumption occurs in the nuclear and aerospace industries, in electrical applications, and in the manufacture of many electronic devices.

Recently, Balmes et al⁵ reported four cases of chronic beryllium disease among workers in a secondary smelter in Connecticut where scraps of beryllium-copper alloys were melted to reclaim copper. The four cases were documented over a period of eight years, and all resembled sarcoidosis. Exposure to beryllium oxide in the melting process was probable.

The similarities between sarcoidosis and beryllium disease have been well established.⁶ Differential diagnosis of sarcoidosis requires the consideration of beryllium disease and a careful review of occupational history. *In vitro* lymphoblast transformation test⁷ and T-lymphocyte count from bronchoalveolar lavage⁸ have been advocated as useful aids for the differential diagnosis. Chemical assays for beryllium in lung tissue, lymph node and urine are useful in evaluation of the individual's exposure.

While the number of beryllium disease cases appears to be waning, its potential still exists in certain industries, as amply illustrated by these clusters. Physicians can play a role in the continued control of beryllium disease by reporting any suspect cases to the U.S. Beryllium Case Registry. Inquiries and reports should be addressed to:

Beryllium Case Registry
The National Institute for Occupational Safety and Health (NIOSH)
Robert A. Taft Laboratory
4676 Columbia Parkway
Cincinnati, Ohio 45226
Attn: Surveillance Branch, F-2
Phone: 513/684-3284

Shiro Tanaka, M.D.; Alexander B. Smith, M.D., M.S.;
William Halperin, M.D., M.P.H.; Robert J. Mullan, M.D.,
National Institute for Occupational Safety and Health (NIOSH),
Cincinnati; and N. Ragner Johnson, M.D., F.C.C.P., Barlow
Hospital, Los Angeles

Reprint requests: Mr. John Sestito, Surveillance Branch, DSHEFS, NIOSH, Mail Stop F-2, 4676 Columbia Parkway, Cincinnati 45226

REFERENCES

- 1 Weber H, Engelhardt WE. Zentralbl Gewerbehyg Unfallverhüt 1933; 10:41-7
- 2 Hardy H. Beryllium Case Registry progress report, 1962. *Arch Environ Health* 1962; 5:265-68
- 3 Eisenbud M. Origins of the standards for control of beryllium disease (1947-1949). *Environ Res* 1982; 27:79-88
- 4 Sprince NL, Kazemi H. U.S. Beryllium Case Registry through 1977. *Environ Res* 1980; 21:44-7
- 5 Balmes JR, Cullen MR, Robins JM. Epidemic chronic beryllium disease among scrap metal refiners. Proceedings, 2nd International Conference on Occupational Lung Disease, March 24-27, 1982. New York: Raven Press (in press)
- 6 Sprince NL, Kazemi H, Hardy HL. Current (1975) problem of differentiating between beryllium disease and sarcoidosis, 1976. *Ann NY Acad Sci* 1976; 278:654-64
- 7 Deodhar SD, Barna B, Van Ordstrand HS. A study of the immunologic aspects of chronic berylliosis. *Chest* 1973; 63: 309-13
- 8 Epstein PE, Dauber JH, Rossman MD, Daniele RP. Bronchoalveolar lavage in a patient with chronic berylliosis: Evidence for hypersensitivity pneumonitis. *Ann Intern Med* 1982; 97:213-16